Form 4: SOPHIA GENETICS SA: CEO Sells Shares for Tax Withholding

SOPHIA GENETICS SA CEO Jurgi Camblong sold 4,486 ordinary shares to cover tax obligations related to restricted stock unit vesting, executed under a Rule 10b5-1 trading plan.

Summary

• Jurgi Camblong, CEO of SOPHiA GENETICS SA, sold 4,486 ordinary shares on May 19, 2026.
• The sale was to satisfy tax withholding obligations due to the vesting of restricted stock units on May 18, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1(c) trading plan.
• The weighted average selling price was $4.6049, with individual sales ranging from $4.54 to $4.71.
• Following these sales, Camblong beneficially owns 3,629,495 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is a planned transaction for tax purposes and not indicative of a negative view on the company's prospects.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, indicating pre-planned and non-discretionary activity.
• The CEO's direct beneficial ownership remains substantial at 3,629,495 shares after the transaction.

Negatives

• A portion of the CEO's shares were sold, reducing his direct holdings.

Risks

• While executed under a plan, any significant selling by key executives can be perceived negatively by the market.
• The need to sell shares for tax obligations, even if planned, indicates a cash flow requirement for the executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which details a specific transaction by an insider.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by SOPHiA GENETICS SA's CEO is a common practice to manage stock sales for liquidity or tax purposes while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The sale is pre-planned and for tax purposes, so it is unlikely to have a significant negative impact, but any insider selling can create short-term market perception issues.
• Employees: The transaction relates to executive compensation and tax obligations, with no direct impact on other employees.
• Management: Demonstrates adherence to regulatory requirements for equity compensation and tax management.

Next Steps

• Continued monitoring of insider trading activity for SOPHiA GENETICS SA.

Key Dates

Keywords

SOPHIA GENETICS SA, Form 4, Insider Trading, Stock Sale, CEO, Tax Withholding, Rule 10b5-1, Restricted Stock Units, Beneficial Ownership